Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized Phase II Study of Dose-Dense FEC75 vs FEC90 as Adjuvant Therapy for Early Breast Cancer
2004-000806-39Phase 2Completed
- Sponsor
- Central European Cooperative Oncology Group
- Start
- Nov 2004
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of epirubicin, fluorouracil, cyclophosphamide and pegfilgrastim in breast cancer (2 arms), sponsored by Central European Cooperative Oncology Group. Primary endpoint: Relative dose intensity of FEC75 vs FEC90. Started Nov 2004; status: completed.
02
Drugs
epirubicinfluorouracilcyclophosphamidepegfilgrastim
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2004-000806-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-000806-39.